Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Wyeth receives green light from CHMP

Wyeth receives green light from CHMP

21st September 2007

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has given Wyeth Pharmaceuticals a positive opinion for the approval of Torisel.

The CHMP’s opinion on Torisel, a therapy intended to treat advanced renal cell carcinoma (RCC), will now be passed on to the European commission for final approval, expected to come in November 2007.

Robert R Ruffolo, president of Wyeth Research stated that the decision underlined the importance of Torisel.

“[Torisel has] been shown to extend median overall survival in patients with advanced kidney cancer when compared with interferon-alpha,” he explained.

Torisel has already received an orphan medicinal product designation in the European Union for the treatment of renal cell carcinoma.

The anticipated European commission final approval will be Torisel’s second green light following the United States Food and Drug Administration’s (FDA) approval in May this year.

According to Cancer Research UK, renal cell cancer accounts for 80 per cent of kidney cancers. The charity claims that although there are different types of renal cell cancers, they are generally treated in the same way.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.